NEW YORK (GenomeWeb News) – Israeli plant genomics firm Evogene today reported a 5 percent increase in revenues for its third quarter.

Evogene said that revenues for the three months ended Sept. 30 totaled $4.2 million, up from $4.0 million a year ago. Its comprehensive loss for the period rose to $2.3 million, or $.06 per share, from a comprehensive loss of $1.0 million, or $.03 per share, in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.